簡體|繁體
Introduction

Essex Bio-Technology Limited (“EssexBio Group” and the “Company”) was incorporated in the Cayman Islands on 31st July, 2000 and has been listed on the Stock Exchange of Hong Kong since 27th June, 2001.
 

Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Group also engaged in the research and development of bFGF products for new indications, as well as other ophthalmic pharmaceutical projects.
 

A series of genetically engineered bio-pharmaceutical drugs have been successfully developed and three of them were classified as State-level Category I new drugs. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin.

 

广告行业赚钱么 幸运赛车精准投注技巧 四川快乐十二前三直选 赛车pk10app 贵州11选五平台 秒速快三官方网址 幸运赛车开奖软件 北京pk赛车预测网 免费 在线配资平台哪家好 湖北快三推荐 新加坡2分彩免费计划